CLINICAL TRIAL: EFFECTS OF ABATACEPT ON THE PROGRESSION OF TYPE 1 DIABATES IN NE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究是一项两组、多中心、随机、双掩蔽、安慰剂对照的II期临床试验。所有组都将接受胰岛素和饮食管理的标准强化糖尿病治疗。108名受试者将按2：1的比例随机分配，接受两年的CTLA-RUG输液或安慰剂输注。这项研究的目的是评估CTLA-Ig输注治疗新发1型糖尿病患者的安全性、有效性和作用方式。将进行评估，以确定受试者是否能够通过CTLA-Ig治疗产生内源性胰岛素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is a two-group, multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial. All groups will receive standard intensive diabetes treatment with insulin and dietary management. 108 subjects will be randomly assigned in a 2:1 ratio to receive either two years of CTLA-rug infusions or placebo infusions. The objective of the study is to assess the safety and efficacy and mode of action of CTLA-Ig infusions for the treatment of individuals with new onset type 1 diabetes. Evaluation will be done to determine if subjects will be able to produce endogenous insulin with the treatment of CTLA-Ig.